Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Revenues Slide, Losses Widen in Q1 of FY05

NEW YORK, July 30 (GenomeWeb News) - Accelrys yesterday reported a sharp drop in revenues and a widening loss for the first quarter of its fiscal year 2005, ended June 30.


The company had $14.2 million in revenues, down from $19.1 million during the same quarter last year. Accelrys attributed this drop in part to a change in revenue recognition for annual and multi-year licenses and smaller consulting and consortia revenues. The change in revenue recognition "will continue to dramatically affect reported revenue through the next three to four quarters," according to a company statement.


Research and development costs stayed flat, at $4.1 million, compared to $4.6 million during the same quarter a year ago.


The net loss for the quarter totaled $6.2 million, or $.25 per share, up from $3.8 million, or $.16 per share, during the year-ago quarter. This included a $1.1 million loss from the discontinued Pharmacopeia Drug Discovery unit.


As of June 30, Accelrys, which changed its name from Pharmacopeia in May, had $83.8 million in cash, restricted cash, cash equivalents, and marketable securities.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.